Facing significant expansion from multinational corporations, Vietnamese drug giants took a hit in 2019 despite new strategies, signalling an uninspiring outlook for future growth.  

While several sectors are being hit by the coronavirus outbreak, the pharmaceutical and healthcare industry is taking an advantage, with numerous expansion strategies among players being placed in the gun barrel.

The past two years have seen capital flows into Vietnam continue to steadily increase, as well as some of the country’s biggest mergers and acquisitions deals to date. 

The Ministry of Health (MOH) estimates that Vietnam has to remit $2 billion abroad to import foreign drugs but could retain more money in-country if it could attract FDI into the pharmaceutical industry.

 VietNamNet Bridge – Expensive imported medicine has been dominating the Vietnamese market, a poor country with the average income per capita at $1,000 a year.